专利号:US-12234495-B2 优先权日:2021-04-06 标 题:Synthesis of beta-hydroxyisovalerate and methods of use 发明人:VEMURI GOUTHAM; LINDSAY CHRISTOPHER; ROBERG-PEREZ KEVIN; SNOW CHRISTOPHER D; CAMERON ELIZABETH A 权利人:SASYA INC 摘要:The biological production of beta-hydroxyisovalerate (βHIV) using at least one non-natural enzyme. The non-natural enzyme for the biologically-derived βHIV provides more beta-hydroxyisovalerate synthase activity than the wild-type parent. The non-natural enzyme having one or more modifications of substrate-specificity positions. The non-natural enzyme can be expressed in a microorganism, such as a yeast or bacteria, wherein the microorganism comprises an active βHIV metabolic pathway for the production of βHIV. Alternatively, the non-natural enzyme can be a βHIV synthase used to produce βHIV in a cell-free environment. The biological derivation of βHIV eliminates toxic by-products and impurities that result from the chemical production of βHIV, such that βHIV produced by a non-natural enzyme prior to any isolation or purification process has not been in substantial contact with any halogen-containing component.
专利号:US-9783485-B1 优先权日:2016-11-30 标题:Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof 发明人:ATTOLINO EMANUELE 权利人:DIPHARMA S A 摘要:The present invention relates to an improved synthesis and crystallization process of the 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, also known as nitisinone or NTBC.
专利号:US-2025002949-A1 优先权日:2021-04-06 标题:Synthesis of beta-hydroxyisovalerate and methods of use
专利号:US-11920177-B2 优先权日:2021-04-06 标题 :Synthesis of beta-hydroxyisovalerate and methods of use
专利号:US-2022315954-A1 优先权日:2021-04-06 标 题 :Synthesis of beta-hydroxyisovalerate and methods of use
专利号:US-2022325304-A1 优先权日:2021-04-06 标 题:Synthesis of beta-hydroxyisovalerate and methods of use
1: Souri E, Lahiji FR, Nourhashemi T, Jalalizadeh H. A Stability Indicating HPLC Method for the Determination of Nitisinone in Capsules. Indian J Pharm Sci. 2015 May-Jun;77(3):348-51. 2: Simoncelli M, Samson J, Bussières JF, Lacroix J, Dorais M, Battista R, Perreault S. Cost-Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I. Can J Hosp Pharm. 2015 May-Jun;68(3):210-7. 3: Mistry JB, Jackson DJ, Bukhari M, Taylor AM. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. Clin Rheumatol. 2015 May 31. [Epub ahead of print] doi: 10.1007/8904_2015_437. Epub 2015 May 5.
合成参考文献
参考文献:10.1111/j.1469-8749.2011.04048.x 摘要:De Laet C, Munoz VT, Jaeken J, François B, Carton D, Sokal EM, Dan B, Goyens PJ. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol. 2011 Oct;53(10):962–4. doi: 10.1111/j.1469-8749.2011.04048.x. 参考文献:10.1007/s10545-011-9374-9 摘要:Ranganath LR, Cox TF. Natural history of alkaptonuria revisited: analyses based on scoring systems. J Inherit Metab Dis. 2011 Dec;34(6):1141–51. doi: 10.1007/s10545-011-9374-9. 参考文献:10.1111/j.1442-200x.2011.03427.x 摘要:Couce ML, Dalmau J, del Toro M, Pintos-Morell G, Aldámiz-Echevarría L; Spanish Working Group on Tyrosinemia type 1. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int. 2011 Dec;53(6):985–9. doi: 10.1111/j.1442-200x.2011.03427.x. 参考文献:10.1371/journal.pbio.1001099 摘要:Wu G, Liu N, Rittelmeyer I, Sharma AD, Sgodda M, Zaehres H, Bleidißel M, Greber B, Gentile L, Han DW, Rudolph C, Steinemann D, Schambach A, Ott M, Schöler HR, Cantz T. Generation of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells. PLoS Biol. 2011 Jul 12;9(7):e1001099. doi: 10.1371/journal.pbio.1001099.